Literature DB >> 12950027

Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification?

Laszlo Hegyi1, Francis H Gannon, David L Glaser, Eileen M Shore, Frederick S Kaplan, Catherine M Shanahan.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare heritable genetic disorder, which is characterized pathologically by sporadic episodes of explosive growth of mesenchymal cells in skeletal muscle followed by cellular differentiation to heterotopic bone through an endochondral process. This study examined the histological origin and differentiation state of stromal cells in early FOP lesions and investigated the association between the phenotype of these FOP cells and bone formation. Interestingly, FOP lesional stromal cells were found to display characteristics of the smooth muscle (SM) cell lineage and are therefore potentially of vascular origin. These cells co-express multiple SM lineage markers along with multiple proteins associated with bone formation including the obligate osteogenic transcription factor Runx2/Cbfa-1. It is hypothesized that the stromal cells of early FOP lesions may be locally recruited vascular cells or cells of the bone marrow stroma and that these cells maintain the potential (given the correct environmental stimuli) to differentiate along an endochondral ossification pathway. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950027     DOI: 10.1002/path.1413

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

1.  Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or--how does one tissue become another?

Authors:  Eileen M Shore
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012 Jan-Feb       Impact factor: 5.814

Review 2.  Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Curr Osteoporos Rep       Date:  2011-06       Impact factor: 5.096

Review 3.  The immunological contribution to heterotopic ossification disorders.

Authors:  Michael R Convente; Haitao Wang; Robert J Pignolo; Frederick S Kaplan; Eileen M Shore
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

Review 4.  Circulating osteogenic precursor cells.

Authors:  Robert J Pignolo; Eileen M Shore
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

Review 5.  Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis.

Authors:  Frederick S Kaplan; Vitali Y Lounev; Haitao Wang; Robert J Pignolo; Eileen M Shore
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

Review 6.  Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons.

Authors:  Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

Review 7.  Inherited human diseases of heterotopic bone formation.

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Nat Rev Rheumatol       Date:  2010-08-10       Impact factor: 20.543

8.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008

9.  Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype.

Authors:  Lixin Kan; Min Hu; William A Gomes; John A Kessler
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 10.  The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-06       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.